We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Motif Bio Plc | LSE:MTFB | London | Ordinary Share | GB00BVVT4H71 | ORD 0.01P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.50 | 0.40 | 0.55 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMMTFB
RNS Number : 0855W
Motif Bio PLC
09 November 2017
9 November 2017
Exercise of Warrants
Motif Bio plc (AIM: MTFB) a clinical stage biopharmaceutical company specialising in developing novel antibiotics announces that it has received notification from warrant holders to exercise warrants representing 207,322 ordinary shares of 1p each ("Ordinary Shares") in the Company at an exercise price of 32.20p per warrant for total consideration of GBP66,757.73.
Application has been made for the 207,322 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on November 14, 2017. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Following Admission, and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 263,336,097 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.
For further information please contact:
Motif Bio plc info@motifbio.com Graham Lumsden (Chief Executive Officer) Robert Dickey IV (Chief Financial Officer) Peel Hunt LLP (NOMAD & BROKER) + 44 (0)20 7418 8900 Dr Christopher Golden Oliver Jackson Northland Capital Partners Limited (BROKER) +44 (0)203 861 6625 Patrick Claridge/ David Hignell John Howes/ Rob Rees (Broking) Walbrook PR Ltd. (FINANCIAL +44 (0) 20 7933 8780 or motifbio@walbrookpr.com PR & IR) Paul McManus Mob: +44 (0)7980 541 893 Mike Wort Mob: +44 (0)7900 608 002 MC Services AG (EUROPEAN IR) +49 (0)89 210 2280 Raimund Gabriel The Trout Group (US IR) + 1 (646) 378-29363 Meggie Purcell mpurcell@troutgroup.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFSUFLUFWSEDF
(END) Dow Jones Newswires
November 09, 2017 09:40 ET (14:40 GMT)
1 Year Motif Bio Chart |
1 Month Motif Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
